Souhaitez-vous accéder aux communiqués récents ?

– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for...

Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients ...

Translational Data Presented at EACCI Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at EACCI 2025

– GALAXIES Lung-201 erfüllte nicht die festgelegten Kriterien für klinisch bedeutsame Verbesserungen beim progressionsfreien Überleben – Ausgehend von der Gesamtheit der Daten haben sich iTeos und...

– L’étude GALAXIES Lung-201 n’a pas satisfait aux critères établis pour une amélioration cliniquement significative de la survie sans progression – Sur la base de l’ensemble des données, iTeos et GSK...

UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on...

– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate the...

- Topline-Zwischenergebnisse von GALAXIES Lung-201 mit >240 Patienten im 2. Quartal 2025 erwartet - Zwischenergebnisse von GALAXIES H&N-202 und TIG-006 HNSCC mit ~200 Patienten 2025 erwartet ...

- Données de haut niveau provisoires issues de l’essai GALAXIES Lung-201, et plus de 240 patients attendus au deuxième trimestre 2025 - Données provisoires issues des essais GALAXIES H&N-202 et...